205 related articles for article (PubMed ID: 18798553)
1. Potent in vitro and in vivo antitumor activity of interleukin-4-conjugated Pseudomonas exotoxin against human biliary tract carcinoma.
Ishige K; Shoda J; Kawamoto T; Matsuda S; Ueda T; Hyodo I; Ohkohchi N; Puri RK; Kawakami K
Int J Cancer; 2008 Dec; 123(12):2915-22. PubMed ID: 18798553
[TBL] [Abstract][Full Text] [Related]
2. Identification, characterization, and targeting of IL-4 receptor by IL-4-Pseudomonas exotoxin in mouse models of anaplastic thyroid cancer.
Joshi BH; Suzuki A; Fujisawa T; Leland P; Varrichio F; Lababidi S; Lloyd R; Kasperbauer J; Puri RK
Discov Med; 2015 Nov; 20(111):273-84. PubMed ID: 26645899
[TBL] [Abstract][Full Text] [Related]
3. Human breast carcinoma cells express type II IL-4 receptors and are sensitive to antitumor activity of a chimeric IL-4-Pseudomonas exotoxin fusion protein in vitro and in vivo.
Leland P; Taguchi J; Husain SR; Kreitman RJ; Pastan I; Puri RK
Mol Med; 2000 Mar; 6(3):165-78. PubMed ID: 10965493
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-4 receptor cytotoxin as therapy for human malignant pleural mesothelioma xenografts.
Beseth BD; Cameron RB; Leland P; You L; Varricchio F; Kreitman RJ; Maki RA; Jablons DM; Husain SR; Puri RK
Ann Thorac Surg; 2004 Aug; 78(2):436-43; discussion 436-43. PubMed ID: 15276492
[TBL] [Abstract][Full Text] [Related]
5. Interleukin 4 receptor on human lung cancer: a molecular target for cytotoxin therapy.
Kawakami M; Kawakami K; Stepensky VA; Maki RA; Robin H; Muller W; Husain SR; Puri RK
Clin Cancer Res; 2002 Nov; 8(11):3503-11. PubMed ID: 12429641
[TBL] [Abstract][Full Text] [Related]
6. Pancreatic cancer cells express interleukin-13 and -4 receptors, and their growth is inhibited by Pseudomonas exotoxin coupled to interleukin-13 and -4.
Kornmann M; Kleeff J; Debinski W; Korc M
Anticancer Res; 1999; 19(1A):125-31. PubMed ID: 10226533
[TBL] [Abstract][Full Text] [Related]
7. A novel fusion toxin derived from an EpCAM-specific designed ankyrin repeat protein has potent antitumor activity.
Martin-Killias P; Stefan N; Rothschild S; Plückthun A; Zangemeister-Wittke U
Clin Cancer Res; 2011 Jan; 17(1):100-10. PubMed ID: 21075824
[TBL] [Abstract][Full Text] [Related]
8. Targeting interleukin-4 receptors for effective pancreatic cancer therapy.
Kawakami K; Kawakami M; Husain SR; Puri RK
Cancer Res; 2002 Jul; 62(13):3575-80. PubMed ID: 12097255
[TBL] [Abstract][Full Text] [Related]
9. Analysis of target genes induced by IL-13 cytotoxin in human glioblastoma cells.
Han J; Yang L; Puri RK
J Neurooncol; 2005 Mar; 72(1):35-46. PubMed ID: 15803373
[TBL] [Abstract][Full Text] [Related]
10. Improved anti-tumor activity and safety of interleukin-13 receptor targeted cytotoxin by systemic continuous administration in head and neck cancer xenograft model.
Kawakami K; Husain SR; Kawakami M; Puri RK
Mol Med; 2002 Aug; 8(8):487-94. PubMed ID: 12435859
[TBL] [Abstract][Full Text] [Related]
11. Human renal cell carcinoma cells are sensitive to the cytotoxic effect of a chimeric protein composed of human interleukin-4 and Pseudomonas exotoxin.
Puri RK; Debinski W; Obiri N; Kreitman R; Pastan I
Cell Immunol; 1994 Apr; 154(1):369-79. PubMed ID: 8131209
[TBL] [Abstract][Full Text] [Related]
12. Analysis of antitumor activity of an interleukin-13 (IL-13) receptor-targeted cytotoxin composed of IL-13 antagonist and Pseudomonas exotoxin.
Kioi M; Kawakami K; Puri RK
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6231-8. PubMed ID: 15448012
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-13 receptor-targeted cancer therapy in an immunodeficient animal model of human head and neck cancer.
Kawakami K; Kawakami M; Joshi BH; Puri RK
Cancer Res; 2001 Aug; 61(16):6194-200. PubMed ID: 11507072
[TBL] [Abstract][Full Text] [Related]
14.
Chang J; Liu X; Ren H; Lu S; Li M; Zhang S; Zhao K; Li H; Zhou X; Peng L; Liu Z; Hu P
Mol Pharm; 2021 Jun; 18(6):2285-2297. PubMed ID: 33998814
[TBL] [Abstract][Full Text] [Related]
15. Development of a recombinant interleukin-4-Pseudomonas exotoxin for therapy of glioblastoma.
Puri RK
Toxicol Pathol; 1999; 27(1):53-7. PubMed ID: 10367674
[TBL] [Abstract][Full Text] [Related]
16. An immunoconjugate of anti-CD24 and Pseudomonas exotoxin selectively kills human colorectal tumors in mice.
Shapira S; Shapira A; Starr A; Kazanov D; Kraus S; Benhar I; Arber N
Gastroenterology; 2011 Mar; 140(3):935-46. PubMed ID: 21147107
[TBL] [Abstract][Full Text] [Related]
17. Cintredekin besudotox in treatment of malignant glioma.
Mut M; Sherman JH; Shaffrey ME; Schiff D
Expert Opin Biol Ther; 2008 Jun; 8(6):805-12. PubMed ID: 18476792
[TBL] [Abstract][Full Text] [Related]
18. Pseudomonas exotoxin A: from virulence factor to anti-cancer agent.
Wolf P; Elsässer-Beile U
Int J Med Microbiol; 2009 Mar; 299(3):161-76. PubMed ID: 18948059
[TBL] [Abstract][Full Text] [Related]
19. Protection of the Furin Cleavage Site in Low-Toxicity Immunotoxins Based on Pseudomonas Exotoxin A.
Kaplan G; Lee F; Onda M; Kolyvas E; Bhardwaj G; Baker D; Pastan I
Toxins (Basel); 2016 Jul; 8(8):. PubMed ID: 27463727
[TBL] [Abstract][Full Text] [Related]
20. IL-4 receptors on human medulloblastoma tumours serve as a sensitive target for a circular permuted IL-4-Pseudomonas exotoxin fusion protein.
Joshi BH; Leland P; Silber J; Kreitman RJ; Pastan I; Berger M; Puri RK
Br J Cancer; 2002 Jan; 86(2):285-91. PubMed ID: 11870521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
